TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Other Accumulated Expenses data on file, last reported at $196000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed 0.0% year-over-year to $196000.0 in Q1 2026; TTM through Mar 2026 was $196000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $196000.0, up 157.89% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $196000.0, roughly flat from $196000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for TCRX reached as high as $1.3 million in Q3 2022 and fell as low as $76000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $358235.3 across 5 years, with a median of $248000.0 in 2024.
• Across the five-year window, Other Accumulated Expenses surged 175.32% in 2023 and tumbled 82.12% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $431000.0 in 2022, then dropped by 1.39% to $425000.0 in 2023, then tumbled by 82.12% to $76000.0 in 2024, then soared by 157.89% to $196000.0 in 2025, then changed by 0.0% to $196000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $196000.0 in Q1 2026, $196000.0 in Q4 2025, and $189000.0 in Q3 2025.